4D pharma plc's (LON:DDDD) Duncan Peyton tells Proactive London's Andrew Scott they're focused on live biotherapeutics - a new class of therapeutics which uses bacteria as drugs.
''Even though it's a new area we've made a lot of progress in the five years we've been going ... we've got our own manufacturing and a really strong IP position and we've just finished some more clinical trials so it's really going well''.
4D has active clinical programmes in areas including oncology and asthma as well as COVID-19 in which they're due to start a Phase II trial shortly.
